Nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with a number of risk factors that can heighten a patient’s risk of major toxicity. Researchers reporting in Arthritis and Rheumatology have come up with a scoring system to measure a patient’s risk of developing major toxicity from NSAID use.
An all-star team of physicians give their takes on how the science behind keeping million dollar athletes on the field has impacted the care patients receive every day.
Patients with systemic lupus erythematosus (SLE) are at an increased risk for fractures, new research shows. The risk is particularly high among patients with lupus nephritis.
Fatigue in patients with systemic lupus erythematosus (SLE) has been linked to anti-NR2 antibodies, which responds to treatment with belimumab, a study shows.
A new study reframes rheumatoid arthritis, broadly considered to be a connective tissue disorder, as having deeper neurological ties.
A pair of phase 3 studies showed 20% symptomatic improvement in patients with psoriatic arthritis who were treated with guselkumab.
Lutikizumab does not improve pain or imaging outcomes for patients with erosive hand osteoarthritis, according to new research.
While gout does not increase the risk of death post-acute coronary syndrome, a new study shows the condition does increase an individual’s risk for readmission after heart failure, as well as the number of days he or she will spend on the hospital.
Even when comorbidities or poor prognosis are considered, osteoporosis specifically, severely raises the risk of hip fracture for women aged 80 or older.
A trio of phase 3 psoriatic arthritis trials showed that 30 mg of apremilast, twice daily, increased the likelihood of achieving low disease activity or remission.
A new study of long-term data demonstrates that infliximab and golimumab are both effective, safe treatments for symptoms of ankylosing spondylitis.
It’s not just weight that could be contributing to degenerative changes in obesity-related osteoarthritis. In this Q&A, Dr. Clifford J. Rosen, director of the Center for Clinical and Translational Research, Maine Medical Center Research Institute, Portland, discusses the mechanisms of osteoarthritis.
Interim results at 24 weeks show that 75.3% of patients treated with tildrakizumab achieved a 20% improvement compared to 50.6% with placebo.
In the phase 3b/4 ORAL Shift study, tofacitinib monotherapy was shown to be comparable to tofacitinib with methotrexate.
Three studies presented this weekend at EULAR in Madrid suggest that being overweight or obese can heighten the severity or arthritic disease.
The overall risk of cancer in psoriatic arthritis patients who are treated with TNF inhibitors doesn’t appear to be linked to their treatment, according to a study presented EULAR this weekend.
A pilot study presented this weekend at EULAR suggests that electro stimulation of the vagus nerve reduces rheumatoid arthritis symptoms.
A 24-week trial of tildrakizumab to treat the skin and joint conditions associated with psoriatic arthritis shows promise as a possible new treatment, shows a study presented at EULAR.
An intensive treatment strategy that combines ebuxostat (Uloric, Takeda) and the novel verinurad, significantly reduced hyperuricemia and albuminuria in patients with type 2 diabetes patients.
A new study of AbbVie’s original JAK1-selective inhibitor indicates that it outdoes adalimumab without sacrificing safety in rheumatoid arthritis treatment.
Lupus nephritis remained in remission for over 10 years in a group of patients who were treated with cyclosporine A, mycophenolate mofetil or azathioprine, shows a study presented at the European Congress of Rheumatology (EULAR) annual meeting this weekend in Madrid.
Patients with rheumatoid arthritis receiving combination treatment were more likely to reach ACR20, ACR50, and ACR70 than those receiving methotrexate monotherapy.
The new study indicated that administration of a bisphosphonate before denosumab treatment, rather than at discontinuation, was far more effective at preventing rebound.
Assorted trials and a long-term exposure study of 3770 patients with rheumatoid arthritis further demonstrate baricitinib’s previously recorded safety profile.
A FUTURE 5 trial and MAXIMIZE trial demonstrate that Cosentyx frequently stops radiographic progression and lessens axial manifestations, respectively.
Ixekizumab (Talz) was significantly more likely to both reduce disease activity by ≥50% and achieve complete skin clearance than adalimumab (Humira).
We have come a long way since the introduction of glucocorticoids for the treatment of systemic lupus erythematosus (SLE). But even with improved treatment and prognosis several challenges remain in the management of SLE. Here, we highlight the 10 most important challenges in treating patients with SLE.
While rituximab has proven to be an effective treatment for rheumatoid arthritis, it has failed to meet its primary endpoints in clinical trials for systemic lupus erythematosus (SLE). But now, an observational study suggests that rituximab could be effective as maintenance therapy in difficult SLE cases.
Reactive arthritis is an inflammatory joint arthritis largely characterized by joint inflammation triggered by infection. To date, no diagnostic or classification criteria have been established, but in 2014, the American College of Rheumatology issued general treatment guidelines. In this article, we highlight a new review article on treatments for reactive arthritis.
A 40-year-old man presents to his primary care doctor complaining of pain in his ankles, knees, feet, heels, lower back and buttocks. What's your diagnosis?
